InvestorsHub Logo

zmanindc

09/03/20 11:20 AM

#295614 RE: Hike #295610

Where do they get 1.1 billion in sales, I count $600 based on Amarin run rate.

Freifaller

09/03/20 11:26 AM

#295618 RE: Hike #295610

Today's decision demonstrates Hikma's ability to successfully challenge patents on important medicines and to provide value to our customers and millions of patients across the United States



That´s a good one. If amarin hadn´t done several trials on vascepa, no one would know the benefits of pure EPA. So without vascepa, there wouldn´t be any value to patients, because there wouldn´t be any generics.

Biobillionair

09/03/20 11:33 AM

#295624 RE: Hike #295610

LMAO...working towards a launch...go for it Hikma..I dare you. BB

sts66

09/03/20 3:43 PM

#295858 RE: Hike #295610

AMRN hasn't sold anywhere close to $1.1B worth of V in the last 12 months - this is why Hikma stock rocketed today, because of that lie!